Peter A Campochiaro Selected Research

Ranibizumab (Lucentis)

10/2022	Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular Degeneration.
1/2022	Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
12/2019	Different Factors Associated with 2-Year Outcomes in Patients with Branch versus Central Retinal Vein Occlusion Treated with Ranibizumab.
1/2019	The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.
12/2016	Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study.
3/2016	Changes in Retinal Nonperfusion Associated with Suppression of Vascular Endothelial Growth Factor in Retinal Vein Occlusion.
1/2016	Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.
7/2015	Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab.
7/2015	Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial.
12/2014	Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter A Campochiaro Research Topics

Disease

57	Macular Edema 01/2022 - 01/2003
50	Choroidal Neovascularization 01/2020 - 04/2002
39	Macular Degeneration (Age-Related Maculopathy) 10/2022 - 01/2006
30	Retinal Vein Occlusion 01/2021 - 08/2007
26	Retinal Neovascularization 01/2020 - 03/2002
26	Rupture 01/2017 - 04/2002
24	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2021 - 06/2002
22	Ischemia 01/2017 - 03/2002
20	Edema (Dropsy) 04/2020 - 11/2009
17	Hypoxia (Hypoxemia) 01/2021 - 11/2003
16	Vascular Diseases (Vascular Disease) 01/2022 - 03/2007
16	Retinitis Pigmentosa (Pigmentary Retinopathy) 01/2022 - 07/2006
12	Retinal Detachment (Retinal Detachments) 01/2022 - 02/2002
12	Neoplasms (Cancer) 10/2019 - 05/2003
12	Retinal Degeneration 01/2018 - 06/2002
8	Retinal Diseases 01/2021 - 09/2003
7	Inflammation (Inflammations) 07/2020 - 11/2009
4	Leukostasis 07/2020 - 01/2007
4	Vitelliform Macular Dystrophy 01/2009 - 02/2003
4	Hyperoxia 11/2007 - 01/2004
3	Vitreous Hemorrhage 01/2022 - 03/2003
3	Disease Progression 01/2021 - 01/2017
3	Hypertension (High Blood Pressure) 12/2019 - 09/2006
3	Ganglion Cysts (Ganglion) 07/2010 - 10/2008
3	Pathologic Neovascularization 05/2009 - 08/2002
3	Epiretinal Membrane (Epiretinal Membranes) 06/2007 - 08/2003
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 07/2015
2	Vision Disorders (Hemeralopia) 12/2020 - 10/2014
2	Fibrosis (Cirrhosis) 01/2020 - 01/2015
2	Hemorrhage 12/2019 - 01/2018
2	Glaucoma 01/2019 - 04/2011
2	Uveitis 01/2019 - 03/2013
2	Eye Diseases (Eye Disease) 10/2018 - 06/2009
2	Atrophy 01/2018 - 01/2015
2	Cataract (Cataracts) 06/2017 - 03/2003
2	Retinopathy of Prematurity (Retrolental Fibroplasia) 01/2017 - 07/2014
2	Retinal Hemorrhage 10/2016 - 01/2012
2	Cicatrix (Scar) 01/2015 - 05/2006

Drug/Important Bio-Agent (IBA)

73	Retinaldehyde (Retinal)IBA 01/2022 - 02/2002
73	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 02/2002
29	Ranibizumab (Lucentis)FDA Link 10/2022 - 12/2006
23	Proteins (Proteins, Gene)FDA Link 10/2020 - 02/2002
11	Oxygen (Dioxygen)IBA 04/2020 - 04/2002
7	Fluorescein (Funduscein)FDA LinkGeneric 01/2015 - 09/2005
7	Messenger RNA (mRNA)IBA 10/2008 - 02/2002
6	Angiopoietin-2IBA 01/2022 - 08/2002
6	Peptides (Polypeptides)IBA 07/2020 - 10/2013
6	afliberceptIBA 01/2018 - 09/2006
6	Fluocinolone Acetonide (Capex)FDA LinkGeneric 01/2017 - 07/2010
6	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 07/2010 - 08/2003
6	pigment epithelium-derived factorIBA 11/2007 - 03/2002
5	Pharmaceutical PreparationsIBA 01/2021 - 03/2004
5	salicylhydroxamic acid (SHAM)IBA 01/2017 - 04/2011
5	Protein Isoforms (Isoforms)IBA 10/2016 - 04/2002
4	Acetylcysteine (Siran)FDA LinkGeneric 01/2021 - 07/2011
4	OpsinsIBA 10/2019 - 09/2009
4	Doxycycline (Periostat)FDA LinkGeneric 01/2018 - 06/2004
4	SteroidsIBA 06/2017 - 03/2013
4	EndostatinsIBA 01/2017 - 05/2003
4	AKB-9778IBA 12/2016 - 10/2014
4	AntioxidantsIBA 06/2009 - 02/2006
4	Phosphotransferases (Kinase)IBA 04/2009 - 08/2003
4	ParaquatIBA 11/2007 - 01/2006
4	midostaurinIBA 03/2004 - 05/2003
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022 - 11/2003
3	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 07/2020 - 08/2011
3	AXT107IBA 07/2020 - 01/2017
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2020 - 01/2007
3	MecamylamineIBA 01/2017 - 04/2008
3	Class 3 Receptor-Like Protein Tyrosine PhosphatasesIBA 12/2016 - 03/2015
3	Proto-Oncogene Proteins c-sis (Platelet Derived Growth Factor B)IBA 03/2013 - 11/2003
3	Bevacizumab (Avastin)FDA Link 09/2009 - 08/2007
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 04/2020 - 08/2015
2	AcriflavineIBA 01/2020 - 01/2017
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 02/2013
2	KetorolacIBA 06/2017 - 02/2003
2	AngiostatinsIBA 01/2017 - 01/2009
2	CollagenIBA 01/2017 - 07/2006
2	chemotactic factor inactivatorIBA 01/2017 - 07/2013
2	Dexamethasone (Maxidex)FDA LinkGeneric 08/2016 - 08/2015
2	Biological ProductsIBA 03/2015 - 09/2006
2	Designed Ankyrin Repeat ProteinsIBA 07/2014 - 04/2013
2	tetrachloroisophthalonitrile (Bravo)IBA 05/2013 - 04/2012
2	fosbretabulin (combretastatin A4)IBA 01/2013 - 08/2003
2	Phosphates (Orthophosphate)IBA 01/2013 - 08/2003
2	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 09/2012 - 11/2007

Therapy/Procedure

34	Intraocular Injections 10/2018 - 06/2002
28	Lasers (Laser) 10/2019 - 04/2002
19	Injections 01/2020 - 05/2003
8	Light Coagulation 01/2017 - 11/2003
5	Intraperitoneal Injections 01/2017 - 07/2002
5	Traction 06/2007 - 02/2002
4	Therapeutics 01/2018 - 11/2007
3	Intravitreal Injections 10/2019 - 11/2009
3	Oral Administration 03/2004 - 09/2002
2	Vitrectomy 01/2017 - 03/2003
2	Subcutaneous Injections 12/2016 - 05/2003
2	Aftercare (After-Treatment) 08/2014 - 06/2004
2	Intravenous Infusions 01/2013 - 02/2008
2	Intravenous Injections 11/2010 - 12/2005